Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 15/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 14/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 14/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26334441 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6367254 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL28949604 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2846979 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6368277 | 1.00 | HTR2C (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL21816672 | 0.98 | HTR2C (0.45) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL377976 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL18081172 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1481267 | 0.80 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL15956717 | 0.78 | CHRNB2 (0.45) | HTR2CCHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-1765327-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2009-06-17 | — | — | EP | claimed |
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | claimed |
| EP-1765327-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | claimed |
| EP-4687894-A1 | COMBINATION THERAPY COMPRISING A PARG INHIBITOR AND A TOPOISOMERASE INHIBITOR FOR TREATING CANCER | Ideaya Biosciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025245087-A1 | HETEROCYCLIC COMPOUNDS AS PARG INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025229549-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PARG | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2025-11-06 | — | — | WO | disclosed |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| EP-4577211-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | Wake Forest University Health Sciences (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025133396-A1 | NOVEL BICYCLO HETEROARYL PARG INHIBITORS | FORX THERAPEUTICS AG (CH) | 2025-06-26 | — | — | WO | disclosed |
| EP-2123647-A1 | 2-(amino-substituted)-4-phenyl pyrimidines useful for treating inflammatory diseases | Millennium Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-1765327-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1959960-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1765327-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| CN-1277824-C | Piperazine derivatives | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | CN | disclosed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| CN-1533382-A | Piperazine derivatives | - | 2004-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HTR2C 3675/4885CHRNB2 4774/4885CHRNA4 4863/4885 |
| US-20250326748-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | HTR2C 4074/4885CHRNB2 2665/4885CHRNA4 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.